Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3016MR)

This product GTTS-WQ3016MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3016MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5097MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ10688MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ1759MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ13877MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ15334MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ5531MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ12051MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ4899MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW